Real-World Effectiveness of Risankizumab for Psoriatic Arthritis Treatment

According to a study published in International Journal of Dermatology, risankizumab showcased substantial improvement in both skin and joint involvement. 

Researchers aimed to assess the effectiveness of the IL-23 inhibitor risankizumab in patients with psoriatic arthritis (PsA) in a real-world setting, as there are limited real-world data available on this treatment. Rheumatologic and dermatologic assessments were conducted at baseline and after 28 to 40 weeks of continuous risankizumab administration, alongside joint and entheses ultrasound assessments.

Results showed a significant decrease in clinical Disease Activity Index for Psoriatic Arthritis scores from a mean of 12.9 ± 7.6 to 7.0 ± 6.1 after treatment. Additionally, the Psoriasis Area and Severity Index score decreased from 8.4 ± 4.9 to 0.3 ± 0.5, and Physician Global Assessment from 3.1 ± 1.0 to 0.4 ± 0.5. These improvements indicate substantial alleviation in both joint and skin involvement following risankizumab treatment.

Moreover, ultrasound assessment revealed a significant reduction in the power Doppler score, indicating decreased inflammation in joints and entheses. Quality of life assessments, measured by the Health Assessment Questionnaire and Dermatology Life Quality Index, were not explicitly mentioned in the summary but could provide further insights into the impact of risankizumab on patients' well-being.

Overall, the study suggests that risankizumab effectively improves both skin and joint manifestations of PsA in a real-world setting, highlighting its potential as a promising treatment option for patients with this condition.

Reference
Graceffa D, Zangrilli A, Caldarola G, et al. Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study. Int J Dermatol. Published online April 7, 2024. doi:10.1111/ijd.17156